This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Biktarvy
  • /
  • Safety and Efficacy of Bictegravir/Emtricitabine/T...
Clinical trial

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Na�ve Adults

Read time: 2 mins
Last updated:13th Nov 2015
Identifier: NCT02607930

The study will evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naive-adults.

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 629 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Actual Study Start Date: November 13, 2015
Actual Primary Completion Date: May 9, 2017
Estimated Study Completion Date: April 2019

- Experimental:
Blinded Phase: B/F/TAF
- Active Comparator: Blinded Phase: ABC/DTG/3TC
- Experimental: Open-Label Phase

Category Value
Date last updated at source 2017-12-05
Study type(s) Interventional
Expected enrolment 629
Study start date 2015-11-13
Estimated primary completion date 2017-05-09

View full details